首頁 > 市場調查報告書 > 製藥

放射性皮膚炎市場規模、佔有率及成長分析（按產品、通路及地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1904281

放射性皮膚炎市場規模、佔有率及成長分析（按產品、通路及地區分類）－2026-2033年產業預測

Radiodermatitis Market Size, Share, and Growth Analysis, By Product (Topical, Oral Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region - Industry Forecast 2026-2033

出版日期: 2025年12月24日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球放射性皮膚炎治療市場規模預計在 2024 年達到 4.7091 億美元，從 2025 年的 4.9022 億美元成長到 2033 年的 6.7607 億美元，在預測期（2026-2033 年）內複合年成長率為 4.1%。

市場分析顯示，放射性皮膚炎治療產品的需求迫切。這種疾病嚴重影響接受放射治療的絕大多數（高達95%）癌症患者，其中乳癌患者的發生率更高。初期，因新冠疫情期間醫療資源優先保障需求，導致放射治療次數減少，市場一度受到衝擊。然而，隨著醫療機構調整策略並優先考慮安全的癌症治療，市場成長機會正在湧現。此外，糖尿病和肥胖症的日益普及也加劇了癌症發生率的上升，相當一部分患者面臨更高的放射性皮膚損傷風險。這些合併症患者風險的增加，也支撐了放射性皮膚炎治療市場在不久的將來強勁的成長潛力。

全球放射性皮膚炎市場促進因素

癌症治療中放射線治療的日益普及是放射性皮膚炎發生率上升的主要原因之一。隨著越來越多的患者接受放射治療，放射性皮膚炎的發生率預計也將相應增加。癌症治療的趨勢也因此推動了對有效放射性皮膚炎管理方案的需求。醫療機構和製藥公司正被鼓勵致力於開發創新治療方法和產品，以滿足因放射暴露而出現皮膚併發症的患者的特殊需求。治療技術的進步與患者照護之間的相互作用，為放射性皮膚炎市場帶來了充滿活力的格局。

限制全球放射性皮膚炎市場的因素

全球放射性皮膚炎市場面臨許多挑戰，其中之一是某些治療方案可能的副作用和不良反應。這些併發症可能會限制某些治療方法在特定患者群體中的適用性，從而阻礙治療方法的普及和療效。醫療專業人員在權衡治療方案的益處和潛在風險時，這些不良反應的存在可能會使患者對某些治療方案望而卻步，最終導致市場成長放緩。因此，透過研發更安全的替代療法來解決這些問題，對於擴大市場規模和改善受影響患者的治療可近性至關重要。

全球放射性皮膚炎治療市場趨勢

全球放射性皮膚炎市場正呈現出顯著的趨勢，即擴大採用先進治療方法。這一趨勢的特點是創新治療方法的使用日益增多，包括專用外用產品和先進敷料，這些療法因其在治療放射性皮膚損傷方面的顯著療效而備受青睞。醫療服務提供者和患者越來越認知到標靶治療不僅能緩解症狀，還能促進皮膚癒合和恢復。因此，對這些最先進治療的需求持續成長，反映出人們在改善放射性皮膚炎患者生活品質和治療效果方面所做的努力。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

3M Company（United States）
Smith & Nephew plc（United Kingdom）
Investor AB（Molnlycke Health Care AB）（Sweden）
BMG Pharma SpA（Italy）
Stratpharma Inc.（Switzerland）
Bausch Health Companies Inc.（Canada）
Bayer AG（Germany）
Paul Hartmann AG（Germany）
KeraNetics, Inc.（United States）
Charles River Laboratories（United States）
The Jackson Laboratory（United States）
InterMed SA（Greece）
AceTech（South Korea）
KCI Licensing Inc.（Acelity）（United States）
Derma Sciences Inc.（Integra LifeSciences）（United States）
Ligand Pharmaceuticals Inc.（Apeiron Biologics）（United States）
Lutris Pharma Ltd.（Israel）
GlaxoSmithKline plc（United Kingdom）
ConvaTec Group plc（United Kingdom）
Viatris Inc（United States）

結論與建議

簡介目錄

Product Code: SQMIG35G2240

Global Radiodermatitis Market size was valued at USD 470.91 Million in 2024 and is poised to grow from USD 490.22 Million in 2025 to USD 676.07 Million by 2033, growing at a CAGR of 4.1% during the forecast period (2026-2033).

Market insights indicate a pressing demand for radiodermatitis treatment products, as this condition significantly impacts a vast majority of cancer patients undergoing radiation therapy-up to 95%, with breast cancer patients experiencing even higher rates. The market faced initial disruptions due to prioritization of COVID-19 healthcare needs, resulting in diminished radiation sessions. However, as healthcare institutions adapt and prioritize safe cancer treatments, growth opportunities are emerging. Additionally, the rising prevalence of diabetes and obesity contributes to an increasing incidence of cancer, with a notable portion of patients facing higher risks of radiation-induced skin damage. This heightened risk among co-morbid individuals underscores a robust potential for growth within the radiodermatitis treatment market in the near future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Radiodermatitis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Radiodermatitis Market Segments Analysis

Global Radiodermatitis Market is segmented by Product, Distribution Channel and region. Based on Product, the market is segmented into Topical, Oral Drugs and Dressings. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Radiodermatitis Market

The growing utilization of radiation therapy in cancer treatment is a significant factor driving the rise in radiodermatitis incidents. As more patients undergo radiation as part of their care regimen, the prevalence of radiodermatitis cases is expected to climb correspondingly. This upward trend in cancer treatment approaches subsequently fuels the demand for effective radiodermatitis management solutions. Healthcare providers and pharmaceutical companies are thus prompted to focus on developing innovative therapies and products to address the unique needs of patients experiencing skin complications from radiation exposure. This synergy between treatment advancements and patient care illustrates the dynamic landscape of the radiodermatitis market.

Restraints in the Global Radiodermatitis Market

The Global Radiodermatitis market faces challenges due to the potential side effects and adverse reactions associated with certain treatment options. These complications can restrict the applicability of various therapies within specific patient demographics, thereby hindering their overall adoption and effectiveness. As healthcare professionals navigate the balance between treatment benefits and possible risks, the presence of these adverse effects could deter patients from pursuing certain therapies, ultimately leading to slower market growth. Addressing these concerns through research and development of safer alternatives may be essential to expanding the market and improving treatment accessibility for affected individuals.

Market Trends of the Global Radiodermatitis Market

The Global Radiodermatitis market is experiencing a notable trend towards the increasing adoption of advanced treatment options. This shift is marked by a rise in the use of innovative therapies, including specialized topical products and advanced dressings, which are becoming favored for their proven efficacy in managing radiation-induced skin damage. Healthcare providers and patients increasingly recognize the importance of targeted therapies that not only alleviate symptoms but also promote skin healing and recovery. As a result, the demand for these state-of-the-art treatments continues to expand, reflecting a broader commitment to enhancing patient quality of life and improving therapeutic outcomes in radiodermatitis management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Technology Assessment
Patent Analysis
Pipeline Analysis

Global Radiodermatitis Market Size by Product & CAGR (2026-2033)

Market Overview
Topical
- Corticosteroids
- Hydrophilic Creams
- Antibiotics
- Others
Oral Drugs
Dressings
- Hydrogel & Hydrocolloid dressings
- No Sting Barrier Film
- Honey-impregnated Gauze
- Silicone Coated Dressings
- Others

Global Radiodermatitis Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Radiodermatitis Market Size & CAGR (2026-2033)

North America (Product, Distribution Channel)
- US
- Canada
Europe (Product, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

3M Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Smith & Nephew plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Investor AB (Molnlycke Health Care AB) (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BMG Pharma S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Stratpharma Inc. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Paul Hartmann AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KeraNetics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charles River Laboratories (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
The Jackson Laboratory (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
InterMed S.A. (Greece)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AceTech (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KCI Licensing Inc. (Acelity) (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Derma Sciences Inc. (Integra LifeSciences) (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ligand Pharmaceuticals Inc. (Apeiron Biologics) (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lutris Pharma Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ConvaTec Group plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments